The Pan-immune-inflammation Value Predicts the Survival of Patients with Breast Cancer

Background: The newly discovered pan-immune-inflammation value (PIV) has been demonstrated to have good prognostic value for cancer patient prognosis. However, the predictive usefulness of PIV in breast cancer patients is unknown. As a result, we did this meta-analysis to investigate the relationship between PIV and the survival of breast cancer patients in order to assist the clinic in offering a unique and reliable biomarker to better evaluate breast cancer patients' prognosis. Methods: We conducted a systematic search of Pubmed, Embase, the Cochrane Library, and the CNKI databases to screen for eligible studies published up to February 25, 2023. Outcomes included overall survival (OS), progression-free survival (PFS), and pathological complete response (pCR). The hazard ratio (HR) and the corresponding 95% confidence interval (CI) were used as the effect indicators. STATA 15.0 software was used to perform meta-analysis, sensitivity analysis, and publication bias analysis. Results: A total of six studies, involving 2744 patients, met the inclusion criteria and were included in this meta-analysis. The results showed that patients with higher PIV levels had a significantly shorter OS (HR: 1.841, 95% CI: 1.354-2.502, P < 0.001) and PFS (HR: 1.513, 95% CI: 1.123-2.040, P = 0.007). Besides, the PIV value was negatively correlated with the efficacy of neoadjuvant chemotherapy. Sensitivity analysis showed that the results of this study were reliable and stable. Conclusions: PIV has a good prognostic value in breast cancer patients and is expected to be a prognostic biomarker for breast cancer.